Dividend25 May 2026, 09:21 pm
Aarti Pharmalabs Recommends ₹2 Final Dividend for FY26
AI Summary
Aarti Pharmalabs Ltd's Board of Directors, in its meeting held on May 25, 2026, approved the audited financial results for the quarter and financial year ended March 31, 2026. The board recommended a final dividend of ₹2 per equity share of face value ₹5 each, subject to shareholder approval. Additionally, Smt. Ketki D. Visariya was re-appointed as Cost Auditor and Manish Modi & Associates as Internal Auditor for FY 2026-27. Mr. Sachin Patil and Mr. Rajendra Pagare were designated as Senior Management Personnel.
Key Highlights
- Aarti Pharmalabs recommends a final dividend of ₹2 per share for FY26.
- Audited financial results for Q4 and FY26 were approved by the board.
- Ketki D. Visariya re-appointed as Cost Auditor for FY27.
- Manish Modi & Associates re-appointed as Internal Auditor for FY27.
- Sachin Patil and Rajendra Pagare designated as Senior Management Personnel.
Price Impact
More from AARTIPHARM